0102030405
News
Dual targets lead the metabolic health revolution. Tirzepatide (2023788-19-2) has become the king of drugs, empowering the global pharmaceutical industry to upgrade
2026-03-12
The global field of metabolic disease treatment has witnessed iterative breakthroughs. The GLP-1/GIP dual-target agonist track continues to explode. As a leading product in this field, Tirzepatid...
view
detail
The GLP-1 track continues to heat up, and Semaglutide (910463-68-2) has made multiple breakthroughs, empowering metabolic health and multi-field scientific research innovation
2026-03-12
In recent years, the global GLP-1 (glucagon-like peptide-1) receptor agonist field has continued to explode. As a core benchmark product in this field, Semaglutide (CAS number: Semaglutide) With ...
view
detail